Skip to main content

Commercial E-Prescribing Cuts Medication Errors in Hospitals

February 1, 2012 — Implementation of 2 commercial e-prescribing systems significantly reduced prescribing errors, including serious errors, at 2 Australian hospitals, according to results from a study published online January 31 in PloS Medicine.
"Considerable investments are being made in commercial electronic prescribing systems (e-prescribing) in many countries," write lead author Professor Johanna Westbrook, PhD, from the University of New South Wales, Sydney, Australia, and colleagues.
However, they note, "Few studies have measured or evaluated their effectiveness at reducing prescribing error rates, and interactions between system design and errors are not well understood, despite increasing concerns regarding new errors associated with system use."
These researchers evaluated the effect of 2 commercially available e-prescribing systems on reducing prescribing errors and assessed their propensity for creating new types of errors.
The authors looked for procedural and clinical errors in medication charts at 2 Sydney teaching hospitals, both before and after the introduction of e-prescribing systems. Procedural errors included unclear, incomplete, or illegal prescribing orders, and clinical errors included prescribing an incorrect drug or incorrect dose.
At hospital A, the Cerner Millennium e-prescribing system was introduced on a single geriatric ward. Three other wards (a renal/vascular ward, a respiratory ward, and another geriatric ward) served as controls.
At hospital B, the researchers compared error rates in 2 wards (psychiatry and cardiology) both before and after the iSoft MedChart system was introduced.
"The introduction of an e-prescribing system was associated with a substantial reduction in error rates in the three intervention wards; error rates on the control wards did not change significantly during the study," the researchers write.
In hospital A, error rates declined from 6.25 (95% confidence interval [CI], 5.23 - 7.28) to 2.12 (95% CI, 1.71 - 2.54; P < .0001) per admission after the e-prescribing system was put into use, the researchers say.
Similar results were seen in hospital B, with error rates falling from 3.62 (95% CI, 3.30 - 3.93) to 1.46 (95% CI, 1.20 - 1.73; P < .0001) per admission.
The researchers attributed the decline in error rates primarily to reductions in procedural errors; clinical errors showed only modest reductions.
However, the authors stress that the introduction of e-prescribing had a significant effect on serious errors, defined as errors that would be likely to lead to death. Rates for serious errors fell across all the intervention wards, from 0.25 per admission to 0.14 per admission (P = .0002), which is a 44% decline.
In contrast, serious error rates in control wards declined by only 17% during the study.
System-related errors (eg, choosing an incorrect drug from a drop-down menu) were responsible for about 35% of the errors seen in the intervention wards after the e-prescribing systems were put into place, the authors write.
That high rate of system-related errors is worrisome, the authors concede, but they say such errors could be corrected by tweaking the systems and improving user training.
The authors point out several limitations of the study, including lack of control wards in hospital B and the inability to randomize hospital wards to the intervention.
Commenting on the study, Lyman Dennis, MBA, PhD, who heads El Dorado Health Consulting in Fairfield, California, told Medscape Medical News, "This study is important because it verifies that electronic systems do improve care, both in terms of improving the accuracy of procedural steps as well as clinical execution. But it also clearly shows that the factor of human error is not removed simply by utilizing these information systems."
Dr. Dennis says another point highlighted by the findings is that hospitals need to have implementation of e-prescribing systems imbedded in some sort of quality improvement process. "You shouldn't have the expectation that when you've finished implementing the system everything is immediately going to proceed smoothly," he said.
Most e-prescribing systems offer a multitude of choices when navigating various screens, and Dr. Dennis points out that although having lots of choices creates flexibility, it can also cause errors. "When many options are offered, making the proper selection can involve a rather fine mouse click, or a fine touch of the screen, and it can be easy to make an incorrect choice," he said.
However, on balance, Dr. Dennis says, e-prescribing makes sense for hospitals. "Though, as we've seen in this study, such systems are associated with an increase in system-related errors, the reduction in serious procedural and clinical errors more than makes up for that," he said.
The research was supported by grants from the National Health and Medical Research Council. One of the study authors has, in the past, had shares and acted as a consultant to give general advice on incident reporting to Patient Safety International. He also was a board member of Patient Safety International, which at that stage was, but is no longer, a subsidiary of the not-for-profit research organization the Australian Patient Safety Foundation, of which he has been and is president. Another coauthor spoke on "Electronic Medication Management and the Hospital Pharmacist" at the Cerner Regional User Group meeting in 2010 at the request of her employer. She personally received no honorarium or fees from this speaking engagement. The other authors and Dr. Dennis have disclosed no relevant financial relationships.
PloS Med. Published online January 31, 2012. Article

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...